Rabies virus vaccine based on vesicular stomatitis virus vector

By inserting rabies virus G protein on the vesicular stomatitis virus vector, the recombinant vaccine was constructed, which solved the high cost of rabies vaccines and the lack of vaccines for wildlife, and achieved efficient and economical rabies vaccine development, which can be used through mosquito vectors and oral treatment. Immunization is carried out in a manner that provides effective prevention of rabies.

CN119040279APending Publication Date: 2024-11-29INST OF ZOOLOGY CHINESE ACAD OF SCI
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202411261067.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing rabies vaccines are costly to produce, lack vaccines and delivery methods for wildlife, and more economical vaccine products are needed in countries with high rabies incidence to achieve single immunization prevention.

Method used

Develop a recombinant vaccine based on vesicular stomatitis virus vector, and construct a recombinant virus by inserting rabies virus G protein before the encapsulation protein G of vesicular stomatitis virus to prevent rabies, and the vaccine can be carried and delivered through mosquito vectors and Immunization is performed by oral administration.

Benefits of technology

A more economical, safe and effective rabies vaccine is achieved, which can effectively infect Aedes aegypti mosquitoes, induce high titer neutralizing antibodies through mosquito carrying, delivery and oral administration, protect mice from rabies virus attacks and is suitable for wild delivery. and wildlife immunization.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention discloses a rabies virus vaccine based on a vesicular stomatitis virus vector. Specifically, the invention discloses a recombinant virus, and the recombinant virus is a recombinant vesicular stomatitis virus for expressing rabies virus PM1503 strain G protein (SEQ ID No.2). The envelope glycoprotein G of the rabies virus PM1503 strain is inserted in front of the envelope protein G of the vesicular stomatitis virus (VSV), and the recombinant virus is recovered. The recombinant virus is high in safety, and vaccine vector virus shedding and spreading cannot be caused when Bama pigs and mice are infected with the recombinant virus. The vaccine can efficiently infect aedes aegypti, and can induce an organism to generate a high-titer neutralizing antibody in a mosquito carrying delivery and oral administration manner, so that the organism is protected from being attacked by rabies virus. The recombinant virus provided by the invention can be used for research, development and preparation of rabies virus vaccines, realizes immunization of wild animal hosts in natural epidemic areas, and is of great significance to protection of wild animals.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, and in particular relates to a rabies virus vaccine based on a vesicular stomatitis virus vector. Background Art

[0002] Rabies, also known as hydrophobia and mad dog disease, is an acute zoonotic central nervous system infectious disease caused by the rabies virus (RABV). Once the disease occurs, the mortality rate is 100%. There is currently no effective treatment drug or method. Rabies virus is mainly present in the salivary glands and saliva of infected animals and is transmitted through animal bites, scratches on the skin or licking of mucous membranes. Vaccinating wild animal hosts of rabies virus, such as dogs, is the most cost-effective way to prevent human rabies because it can block transmission at the source. In addition, vaccinating wild animals can also reduce the need for post-exposure prophylaxis. RABV belongs to the genus Lyssavirus of the family Rhabdoviridae. It is an enveloped single-stranded negative-sense RNA virus that contains five structural proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M), envelope glycoprotein (G) and RNA-dependent RNA polymerase (L). The glycoprotein G of the rabies virus is a transmembrane protein with a trimeric structure that constitutes the spikes on the surface of the virus. It is the only rabies virus antigen discovered so far that can stimulate the body to produce neutralizing antibodies, and it is also the only ingredient present in all new rabies vaccines.

[0003] Traditional rabies vaccines are composed of attenuated or inactivated rabies viruses. From nerve tissue vaccines starting with Pasteur rabies vaccines to avian embryo vaccines and then to cell culture vaccines, rabies vaccines have been continuously improved and perfected. At present, rabies virus vaccines cultured in Vero cell lines have been mass-produced and widely used in the prevention and post-exposure vaccination of rabies in humans and animals. Traditional vaccines contain antigens with the same characteristics as wild strains, which can induce the body to produce virus-neutralizing antibodies against glycoprotein G, while activating helper T cells and cytotoxic T cells, thereby protecting against the lethal attack of lethal rabies viruses. However, the production cost of the traditional rabies vaccines currently used is high, there is a lack of vaccines for wild animals and the method of delivery, and there are certain production and use risks. In addition, in some countries with a high incidence of rabies, more economical vaccine products are still needed for single immunization to achieve the purpose of preventing rabies. Therefore, the development of a more economical, safe and effective new rabies vaccine has become the focus of more and more researchers.

[0004] Among various vaccine forms, live virus vector vaccines have become the focus of new vaccine research and development because they can induce the strongest immune response and the best protective effect. The choice of viral vector is the key to the success of the vaccine. Vesicular Stomatitis Virus (VSV) is a representative model virus of the Rhabdoviridae family and is widely used to study the mechanisms of invasion, replication and assembly of enveloped RNA viruses. Vesicular stomatitis caused by VSV is a benign disease transmitted by contact. It mainly infects rodents, cattle, pigs and horses, and can also infect humans and other animals. The lack of VSV antibodies and the lack of obvious pathogenicity are the prerequisites for VSV to be used as a vaccine and therapeutic viral vector. VSV is a single-stranded negative-stranded non-segmented RNA virus with a genome length of about 11Kb and a simple structure. Five mRNAs are transcribed from 3' to 5', encoding five proteins: nucleocapsid protein N, phosphoprotein P, matrix protein M, glycoprotein G, and large polymerase L. G protein is a type I integral membrane protein that exists in the form of a trimer on the surface of viral particles and performs the functions of binding to target cell receptors and membrane fusion. Summary of the invention

[0005] The technical problem to be solved by the present invention is how to prevent rabies. The technical problem to be solved is not limited to the described technical subject matter, and those skilled in the art can clearly understand other technical subjects not mentioned in this article through the following description.

[0006] In order to solve the above technical problems, the present invention first provides a recombinant virus, which may be a recombinant vesicular stomatitis virus expressing rabies virus G protein.

[0007] The recombinant virus may be a recombinant virus obtained by inserting the rabies virus G protein in front (N-terminus) of the envelope protein G (G protein) of the vesicular stomatitis virus (VSV).

[0008] Furthermore, the matrix protein M (M protein) of the vesicular stomatitis virus may lack the 51st amino acid - methionine.

[0009] The rabies virus G protein may be derived from the rabies virus (RABV) PM1503 strain.

[0010] Furthermore, the amino acid sequence of the rabies virus G protein may be as shown in SEQ ID No.2.

[0011] Furthermore, the recombinant virus may contain a nucleic acid molecule encoding the rabies virus G protein described herein, and the nucleic acid molecule may be located between the M protein gene and the G protein gene of the vesicular stomatitis virus.

[0012] Furthermore, the nucleotide sequence of the nucleic acid molecule may be as shown in SEQ ID No.1.

[0013] The present invention also provides a method for preparing any of the recombinant viruses described herein, the method may comprise the following steps: A1) introducing the nucleic acid molecule encoding the rabies virus G protein described herein into a vesicular stomatitis virus vector to obtain a recombinant vesicular stomatitis virus vector expressing the rabies virus G protein; A2) rescuing the recombinant vesicular stomatitis virus vector to obtain the recombinant virus.

[0014] In the above method, the introduction in A1) may be introducing the nucleic acid molecule between the M protein gene and the G protein gene of the vesicular stomatitis virus vector.

[0015] The method for rescuing the virus in A2) can be: co-transfecting the recombinant vesicular stomatitis virus vector and the helper plasmid into a host cell, and obtaining the recombinant virus through culture; the helper plasmid includes a plasmid expressing the vesicular stomatitis virus N protein, a plasmid expressing the vesicular stomatitis virus P protein, a plasmid expressing the vesicular stomatitis virus L protein, a plasmid expressing the vesicular stomatitis virus M protein, a plasmid expressing the vesicular stomatitis virus G protein, and a plasmid expressing T7 RNA polymerase.

[0016] In the above method, the host cell may be a packaging cell. The packaging cell is used to package a viral vector plasmid lacking at least one gene encoding a protein required for viral packaging, which can provide comprehensive viral proteins for viral packaging into recombinant viruses, and itself cannot produce any form of viral particles. Any cell that provides a protein or polypeptide lacking in viral packaging can be considered as a packaging cell. Suitable packaging cells are well known to those skilled in the art, such as ECO cells, PG13 cells, HEK293 cells, CHO cells, 293T cells, 293 cells, MDCK cells, NIH3T3 cells, PA317 cells, COS cells, HeLa cells, Vero cells, PsiCRIP cells, etc. In one or more embodiments of the present invention, the host cell (packaging cell) is a Vero cell.

[0017] In the above method, the nucleotide sequence of the nucleic acid molecule may be as shown in SEQ ID No.1.

[0018] In the above method, the auxiliary plasmid can be a recombinant expression vector obtained by cloning a nucleic acid molecule encoding a protein required for virus rescue into an expression vector. The expression vector is not limited to a specific vector, and those skilled in the art can use a suitable expression vector, such as pCDNA3.1(-), pCDNA3.1(+), PYES2.0, pBI121 and pPIC9K, etc. As long as the expression vector can express the protein required for virus rescue.

[0019] The proteins required for virus rescue include vesicular stomatitis virus N protein, vesicular stomatitis virus P protein, vesicular stomatitis virus L protein, vesicular stomatitis virus M protein, vesicular stomatitis virus G protein and T7 RNA polymerase.

[0020] In the above method, the vesicular stomatitis virus vector may be rVSV-G ΔM51.

[0021] The Genebank accession number of the nucleotide sequence of the vector rVSV-G ΔM51 is: NC_038236.1 (11162 bp).

[0022] Furthermore, the recombinant vesicular stomatitis virus vector described herein may also include a reporter gene.

[0023] Furthermore, a reporter gene may be introduced into the vesicular stomatitis virus vector (eg, rVSV-G ΔM51).

[0024] Further, the reporter gene may include, but is not limited to, β-glucuronidase (GUS) gene, luciferase (Luciferase) gene, chloramphenicol acetyltransferase (CAT) gene, β-galactosidase (β-gal) gene, secretory human placental alkaline phosphatase (SEAP) gene, yellow fluorescent protein (YFP) gene and green fluorescent protein (GFP) gene. In one or more embodiments of the present invention, the reporter gene is GFP gene.

[0025] Any of the recombinant vesicular stomatitis virus vectors described herein is also within the scope of protection of the present invention.

[0026] The present invention also provides a vaccine prepared by any of the recombinant viruses or the recombinant vesicular stomatitis virus vectors described herein.

[0027] The active ingredient of the vaccine may include any of the recombinant viruses described herein.

[0028] The vaccine can be used to prevent rabies virus infection or rabies; the vaccine can also be used to provide an immune response against rabies virus.

[0029] The vaccine may further include an adjuvant.

[0030] The term "adjuvant" refers to a substance that can stimulate the body to produce a stronger humoral and / or cellular immune response to the antigen vaccinated with it. The adjuvants described herein are well known to those skilled in the art, including but not limited to: plant adjuvants (such as alkylamines, phenolic components, quinine, saponin, sesquiterpenes, proteins, polypeptides, polysaccharides, glycolipids, phytohemagglutinins, etc.), bacterial adjuvants (such as cholera toxin, Escherichia coli heat-labile toxin, bacterial lipopolysaccharide, etc.), aluminum adjuvants and other inorganic adjuvants (such as calcium adjuvants), cytokines and nucleic acid adjuvants (such as monocyte colony stimulating factor, leukocyte factors IL-1, IL-2, IL-4, IL-5, IL-6, IFN-γ, CpG motifs, nucleic acid vectors, etc.), emulsion adjuvants (such as Freund's adjuvant).

[0031] The present invention also provides the use of any of the recombinant viruses described herein or the recombinant vesicular stomatitis virus vectors in the preparation of a product (such as a vaccine) for preventing rabies virus infection or rabies.

[0032] The present invention also provides a method for preparing insects for immunization, the method comprising infecting insects with any of the recombinant viruses described herein to obtain the insects for immunization.

[0033] The insects may be insects that can spread viruses, including but not limited to mosquitoes, sand flies, black flies, blood-sucking midges, flies, fleas, lice, cockroaches, bedbugs, ants, etc.

[0034] Furthermore, the insect may be an insect of the family Culicidae, such as Aedes aegypti and Aedes albopictus.

[0035] The method for preparing the insect for immunization may specifically include feeding mosquito insects with a mixture of the recombinant virus and blood.

[0036] Vesicular stomatitis virus (VSV) is a live virus vaccine vector and a representative model virus of the Rhabdoviridae family. Its vectors include mosquitoes, sand flies, black flies, and blood-sucking midges. Through genetic modification, VSV can express exogenous antigenic proteins and induce the body to produce a specific immune response to the antigen, and is used as a vaccine vector.

[0037] Molecular genetics research on VSV virus requires the establishment of a system to restore DNA to infectious virus. The present invention transfects a plasmid encoding a viral transcription complex (N, P, M, L, G) and T7 polymerase, and at the same time transfects a T7 promoter plasmid encoding a full-length viral antisense genome. The harvested cell supernatant was proven to contain infectious virus particles. The present invention successfully recovers infectious VSV virus from DNA, making it possible to genetically manipulate VSV. Exogenous viral functional envelope proteins with suitable cytoplasmic tails can be effectively packaged into the viral envelope to form various chimeric recombinant VSV carrying heterologous envelope proteins. The non-coding region between each transcription unit of the recombinant VSV can tolerate the insertion of up to 4.5kb of exogenous genes and obtain efficient expression. As a live vector vaccine, VSV has the following advantages: (1) Easy to culture: VSV can obtain very high titers on most mammalian cells and is easy to prepare in large quantities. (2) High efficiency: In the VSV-HA infected mouse model, the immune response induced by 10 infectious virus particles was as significant as that induced by 105 infectious particles. (3) Easy to use: Immunization can be carried out through a variety of vaccination routes, and a single vaccination can often induce a strong immune response. (4) It can stimulate the body to produce strong cellular and humoral immune responses. It can also induce a strong mucosal immune response: it is particularly suitable for the development of vaccines for respiratory pathogens that infect through the mucosa. (5) Good safety: Since the VSV virus replicates completely in the cytoplasm, only from RNA→RNA, it will not integrate into the DNA of the host cell and will eventually be eliminated by the host immune system. Moreover, through reverse genetic manipulation to perform genome mutations and modifications, the VSV virus can be appropriately weakened to make it a safer recombinant vaccine vector. In addition, since the VSV envelope protein has both receptor recognition and membrane fusion functions, its recognition receptors are widely present on the surface of various tissue cell membranes, making VSV extremely tissue-tropic. These characteristics give VSV the potential for application as a new expression vector and live virus vaccine vector.

[0038] The present invention utilizes a viral vector system (rVSV), which can directly produce RABV G protein with natural structure and immunogenicity in animals, and can stimulate the body's immune response to produce specific antibodies that can resist rabies virus attack. The viral vector vaccine in the present invention is simpler and more direct for rabies immunization, and is a cheaper and more efficient vaccine compared to other genetically engineered vaccines and traditional cell culture vaccines. The rVSV-RABV GG ΔM51 recombinant virus in the present invention can stimulate experimental animals to produce high levels of specific neutralizing antibodies by oral administration, and 100% protect mice from rabies virus attack. The oral immunization route provides a basis for field delivery. And the recombinant virus can efficiently infect Aedes aegypti, and immunity to wild animal hosts in natural epidemic areas can be achieved by mosquitoes carrying vaccines to deliver immunity.

[0039] In summary, in order to achieve the prevention of rabies, the present invention has developed a viral vaccine based on a vesicular stomatitis virus vector. The present invention inserts the envelope glycoprotein G of the rabies virus PM1503 strain before the envelope protein G of the vesicular stomatitis virus (VSV), and restores the recombinant virus. The recombinant virus has high safety, and the infection of Bama pigs and mice will not cause the shedding and spread of the vaccine vector virus. And the vaccine of the present invention can efficiently infect Aedes aegypti, and can induce the body to produce high-titer neutralizing antibodies through mosquito-carrying delivery and oral administration, protecting it from the attack of rabies virus. The recombinant rabies virus based on vesicular stomatitis virus VSV constructed by the present invention can be used for the development and preparation of rabies virus vaccines, and the recombinant virus can be carried and delivered by mosquito vectors and orally administered to wild hosts for rabies vaccine immunization. Immunization of wild animal hosts in natural epidemic areas will be of great significance to the development of rabies virus vaccines and the protection of wild animals. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 Schematic diagram of the structure of the recombinant viral vector rVSV-RABV GG ΔM51 expressing the G protein of RABV PM1503 strain.

[0041] Figure 2 This is the identification result of the recombinant virus rVSV-RABV GG ΔM51 in Example 1.

[0042] Figure 3 The safety test results of the recombinant virus rVSV-RABV GG ΔM51 in Example 2 (virus shedding test results in pigs).

[0043] Figure 4 To implement 2. The transmission safety test results of the recombinant virus rVSV-RABV GG ΔM51 candidate vaccine (virus shedding test results in mice).

[0044] Figure 5 These are the test results of the recombinant virus rVSV-RABV GG ΔM51 infecting Aedes aegypti in Example 3 (the test results of the virus titer in the mosquito).

[0045] Figure 6 These are the results of oral immunization and protective effect testing of the recombinant virus rVSV-RABV GG ΔM51 in Example 4.

[0046] Figure 7 This is the test result of immunizing mice with the recombinant virus rVSV-RABV GG ΔM51 in Example 4 via the Aedes aegypti delivery route. DETAILED DESCRIPTION

[0047] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0048] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0049] The GenBank accession number of the GFP gene in the following examples is AHL68672.1.

[0050] The plasmid expressing the N protein of VSV in the following embodiments is a plasmid obtained by cloning the N protein encoding gene sequence in the VSV genome into the eukaryotic expression plasmid pCDNA3.1(+) (Beijing Shengyuan Kemeng Gene Biotechnology Co., Ltd.) through the BamHI and EcoRI restriction sites. The plasmid of the P protein is a plasmid obtained by cloning the P protein encoding gene sequence in the VSV genome into the eukaryotic expression plasmid pCDNA3.1(+) (Beijing Shengyuan Kemeng Gene Biotechnology Co., Ltd.) through the BamHI and EcoRI restriction sites. The plasmid of the M protein is a plasmid obtained by cloning the M protein encoding gene sequence in the VSV genome into the eukaryotic expression plasmid pCDNA3.1(+) (Beijing Shengyuan Kemeng Gene Biotechnology Co., Ltd.) through the BamHI and EcoRI restriction sites. The plasmid of the G protein is a plasmid obtained by cloning the G protein encoding gene sequence in the VSV genome into the eukaryotic expression plasmid pCDNA3.1(+) (Beijing Shengyuan Kemeng Gene Biotechnology Co., Ltd.) through the BamHI and EcoRI restriction sites. The plasmid for L protein is obtained by cloning the L protein coding gene sequence in the VSV genome into the eukaryotic expression plasmid pCDNA3.1(+) (Beijing Shengyuan Kemeng Gene Biotechnology Co., Ltd.) through the BamHI and EcoRI restriction sites. The plasmid for expressing T7 RNA polymerase is obtained by cloning the T7 RNA polymerase coding gene sequence into the eukaryotic expression plasmid pCDNA3.1(+) (Beijing Shengyuan Kemeng Gene Biotechnology Co., Ltd.) through the BamHI and EcoRI restriction sites.

[0051] The Bama pigs and Aedes aegypti in the following examples are both common species and are commercially available.

[0052] The rabies virus CVS-11 strain in the following examples was purchased from Jilin Heyuan Bioengineering Technology Innovation Research and Development Co., Ltd.

[0053] The vesicular stomatitis virus in the following embodiment is recorded in the document "Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus. NPJ Vaccines. 2019 Jan 25;4:5.", which is available to the public from the Institute of Zoology, Chinese Academy of Sciences. The biological material is only used to repeat the relevant experiments of the present invention and cannot be used for other purposes.

[0054] Example 1. Preparation of recombinant virus rVSV-RABV GG ΔM51 1. Preparation of recombinant vector rVSV-RABV GG ΔM51 In order to develop a rabies virus vaccine for wild animals, the present invention inserts the coding gene of glycoprotein G (gene bank accession number P15199.2) of RABV PM1503 strain into the vesicular stomatitis virus vector rVSV-G ΔM51, and simultaneously inserts a reporter gene expressing GFP to obtain a recombinant virus vector expressing the G protein of RABV PM1503 strain. The structural schematic diagram is shown in FIG. Figure 1 As shown, the gene encoding glycoprotein G of the above RABV PM1503 strain is inserted into the front (N-terminus) of the envelope protein G and the back (C-terminus) of the matrix protein M in the viral vector rVSV-G ΔM51, and the constructed recombinant vector is named rVSV-RABV GG ΔM51.

[0055] Among them: the amino acid sequence of the G protein of the RABV PM1503 strain is shown in SEQ ID No.2, and the nucleotide sequence of its encoding gene is shown in SEQ ID No.1.

[0056] Vesicular stomatitis virus vector rVSV-G ΔM51 is a rVSV-G vector with the 51st amino acid of the M segment deleted. Vesicular stomatitis virus vector rVSV-G ΔM51 was synthesized by Beijing Shengyuan Kemeng Gene Biotechnology Co., Ltd., and the gene sequence is NC_038236.1.

[0057] The specific construction method of the recombinant vector rVSV-RABV GG ΔM51 is as follows: the sequence of SEQ ID No.1 is inserted between the restriction sites MluI and NotI of the rVSV-G ΔM51 vector, and the GFP gene is inserted between the restriction sites BamHI and EcoRI of the rVSV-G ΔM51 vector to obtain a recombinant vector, which is named recombinant vector rVSV-RABV GG ΔM51.

[0058] 2. Rescue of recombinant virus rVSV-RABV GG ΔM51 The recombinant vector rVSV-RABV GG ΔM51 prepared in step 1 and auxiliary plasmids (a plasmid expressing N protein of VSV, a plasmid expressing P protein of VSV, a plasmid expressing L protein of VSV, a plasmid expressing M protein of VSV, a plasmid expressing G protein of VSV, and a plasmid expressing T7 RNA polymerase) were co-transfected into Vero cells to prepare the recombinant virus rVSV-RABV GG ΔM51. The specific steps are as follows: 1) Vero cells (from ATCC, catalog number CCL-81) were passaged into culture dishes. When the cell density reached 70%-80% on the second day, the complete culture medium was replaced with DMEM medium (Thermo Fisher, catalog number SH30243.01B) containing 2% (volume fraction) fetal bovine serum (FBS, Thermo Fisher, catalog number 10091) to obtain the Vero cell culture system.

[0059] 2) After completing step 1), incubate 36 μL of FuGENE 6 (Promaga, catalog number E2692) and Opti-MEM medium (Thermo Fisher, catalog number 51985091) at room temperature for 5 minutes, mix with the recombinant vector rVSV-RABV GG ΔM51 (1.59 μg), plasmid expressing VSV N protein (1.286 μg), plasmid expressing VSV P protein (639 ng), plasmid expressing VSV L protein (159.9 ng), plasmid expressing VSV M protein (159.9 ng), plasmid expressing VSV G protein (159.9 ng), and plasmid expressing T7 RNA polymerase (8.1 μg) in step 1, and incubate at room temperature for 15 minutes to obtain the incubated solution (total volume 600 μL).

[0060] 3) After completing step 2), add the incubated solution in step 2) to the Vero cell culture system in step 1), and replace with fresh culture medium after 6 hours. Collect the cell supernatant 3 days after transfection, which contains the recombinant virus rVSV-RABVG-G ΔM51. Infect new Vero cells with the obtained supernatant to achieve the amplification of the recombinant virus rVSV-RABV GG ΔM51. The recombinant virus rVSV-RABV GG ΔM51 is a virus obtained by inserting the coding gene sequence of rabies virus G protein before the coding gene sequence of glycoprotein G in the vesicular stomatitis virus genome sequence.

[0061] 3. Identification of recombinant virus rVSV-RABV GG ΔM51 Vero cells were passaged in a 10 cm cell culture dish at a ratio of 1:3. The next day, when the cells grew to a density of about 80%, the recombinant virus rVSV-RABV GG ΔM51 prepared in Example 1 was added, with an MOI of 0.01. After 3 hours of infection, the medium was replaced with DMEM medium containing 2% (volume fraction) FBS. Samples were taken every 12 hours after infection until 120 hours after infection. The virus titer in the supernatant at different infection times was measured. The results are shown in Figure 2. Figure 2 As shown, the virus titer of the recombinant virus rVSV-RABV G-GΔM51 can reach 10 within 48-60 hours of infection. 8 FFU / mL.

[0062] The virus titer was detected by direct fluorescence method, and the specific steps are as follows: Vero cells were passaged in a 96-well plate at a rate of 10,000 cells per well. The next day, when the cells grew to a density of about 80%-90%, the virus supernatant to be tested was added. The virus supernatant was diluted 10 times in a gradient, that is, 30 μl of the virus stock solution was mixed with 270 μl of the virus dilution solution, and so on, for a total of 6-7 gradient dilutions. The virus dilution solution was DMEM culture medium containing 2% (volume fraction) FBS. 100 μl of virus solution was added to each well, and 3 wells were set up for each dilution. The cells were placed in a 37°C cell culture incubator, and the medium was replaced with 20 mM NH after 2 hours of infection. 4 Cl and 2% (volume fraction) FBS DMEM medium, the cells were placed in a 28 ° C cell culture incubator. 24 hours after infection, the number of fluorescent cells in the 96-well plate was selected to be 10 2 The calculation method is: average fluorescence count in three wells × dilution factor × 10. For example, if the dilution factor is 10 4 The fluorescence in the wells is 21, and the virus titer is 21×10 4 ×10=2.1×10 6 FFU / ml.

[0063] Example 2. Safety testing of the recombinant virus rVSV-RABV GG ΔM51 1. Safety of the recombinant virus rVSV-RABV GG ΔM51 in Bama pigs Bama pigs aged 3-5 weeks were selected as experimental animals. On day 0, 6 Bama pigs were injected intradermally at the nasal tip with a dose of 10 6 FFU / head. The weight and body temperature of the animals were monitored and recorded every day before vaccination and on days 1-7 after vaccination. About 500 ul of blood samples were collected before vaccination and on days 1, 3, 5, and 7 after vaccination for the detection of viremia, and the blood samples were placed in EP tubes containing anticoagulants. Nasal swabs, pharyngeal swabs, and rectal swabs were collected before vaccination and on days 1, 3, 5, and 7 after vaccination and placed in EP tubes containing RNALater. On the third day after vaccination, three animals in the experimental group were euthanized, and the tongue, nose, lips, brain, heart, liver, spleen, lungs, kidneys, and trachea were dissected for the detection of virus shedding. The samples were divided into two tubes and placed in EP tubes. On the 14th day after vaccination, about 1 ml of whole blood was taken from the remaining three experimental animals to prepare serum, which was stored at -80°C.

[0064] The swabs, tissues and blood at each time point were tested for viral nucleic acid. Figure 3 As shown, the experimental animals did not lose weight after vaccination, and the quantitative test results of swabs and blood samples did not find virus shedding. For the tissue test of euthanized animals, only a low dose of viral nucleic acid was detected in the tongue tissue of one animal on the third day of vaccination. A high level of neutralizing antibodies was detected in the experimental group animals 14 days after vaccination. In summary, although the VSV vector recombinant virus can replicate in pigs, the virus does not cause obvious clinical disease and the amount of virus shedding is very small.

[0065] 1.1. The specific steps for viral nucleic acid detection are as follows: The qRT-PCR method was used to detect the viral load in each sample using the One Step TB PrimeScriptTM RT-PCR Kit (Cat. No.: RR066A, Manufacturer: TaKaRa). Primer information: NF: CGGAGGATTGACGACTAATGC, NR: ACCATCCGAGCCATTCGA. The reaction system is shown in Table 1.

[0066]

[0067] The reaction program was set as reverse transcription reaction: 42°C 5min, 95°C 10sec; PCR reaction: number of cycles: 40, 95°C 5sec, 60°C 30sec.

[0068] 1.2. The specific steps for neutralizing antibody detection are as follows: Vero cells were passaged in 96-well plates at a density of 10,000 cells per well. The next day, when the cells grew to about 80%-90%, the experiment was ready. First, the serum was diluted by 5-fold dilution method, such as 1:10, 1:50, 1:250, 1:1250. At the same time, the rVSV-GFP-SARS-CoV-2 virus was diluted to 2×10 3 FFU / ml, so that the final virus count in each well is 100 FFU. In an empty 96-well plate, add an equal amount of the diluted virus solution to each well, add the same amount of serum one by one according to the corresponding dilution ratio, and then mix well. After mixing, the serum dilution multiple becomes twice the original dilution number. After incubation at room temperature for 30 minutes, take 100 μl of the mixture and cover the Vero cell layer. After 2 hours, replace the 20mM NH 4 Cl medium, and read the number of GFP-positive cells in each well under a fluorescence microscope after 24 hours. Calculate the neutralizing antibody titer (FRNT50) according to the Reed Muench method. Calculation formula: FRNT50 = [1 / 10] (小于50%细胞感染数稀释倍数的对数+距离比例×稀释系数的对数) Distance ratio = (50% - less than 50% cell infection number positive rate) / (greater than 50% cell infection number positive rate - less than 50% cell infection number positive rate). The dilution factor is the multiple dilution gradient.

[0069] 2. Transmission safety of the recombinant virus rVSV-RABV GG ΔM51 candidate vaccine In order to verify that animals infected with high-dose VSV vector recombinant virus are not easily transmitted to uninfected animals and are an ecologically safe vaccine vector, we conducted experiments using BALB / c mice. First, two mice were inoculated with 10 6 FFU virus, the inoculated mouse was housed with three uninoculated mice. Two replicates were set up, i.e. Figure 4 Group 1, Group 2. Figure 4 As shown, no weight loss was found in the contact control mice during the feeding period, and no shedding of vaccine virus was detected in the blood according to the viral nucleic acid detection method in Example 2. This shows that the VSV vector recombinant virus cannot be easily transmitted to unvaccinated animals even after long-term contact.

[0070] Example 3: Detection of recombinant virus rVSV-RABV GG ΔM51 infecting Aedes aegypti The recombinant virus rVSV-RABV GG ΔM51 (10 8FFU / ml) is inoculated into 5-6 day old Aedes aegypti mosquitoes by blood sucking. 5-6 day old female mosquitoes need to be starved for 16-24 hours before being infected with the virus. On the day of blood sucking and infecting mosquitoes, 600 μl of mouse blood and virus mixture (50% mouse blood and 50% virus liquid) is preheated in a 37°C water bath for 30 minutes. Then add the blood and virus mixture to the blood feeder, which is connected to a 37°C circulating water bath. The mosquitoes can suck the virus mixture through a very thin sealing film for 30 minutes. After the mosquitoes are full of blood, they are placed in a 4°C refrigerator for 5-10 minutes. After they are frozen and fainted, they are placed on ice, and the full-blooded mosquitoes are picked out and placed in a constant temperature and light incubator at 28°C for breeding. After 10 days, the Aedes aegypti mosquitoes are taken and ground to detect the virus titer in a single Aedes aegypti mosquito. The detection method is the same as in Example 1. The results are as follows Figure 5 As shown, the virus titer of a single Aedes aegypti mosquito can reach 10 5.5 FFU / mL, the titer of salivary gland virus can reach 10 3.3 FFU / mL.

[0071] Example 4. Immunogenicity and protective effect detection of recombinant virus rVSV-RABV GG ΔM51 1. Oral immunization and protective effect of recombinant virus rVSV-RABV GG ΔM51 Experimental animals: BALB / c mice (Wei Tong Li Hua Laboratory Animal Technology Co., Ltd., female, 8 weeks old).

[0072] Experimental method: The recombinant virus rVSV-RABV GG ΔM51 prepared in Example 1 was orally inoculated into BALB / c mice and divided into 10 7 FFU and 10 6 Two doses of FFU, single immunization, 12 mice per group. Blood was collected 28 days after inoculation to test the neutralizing antibody titer. The neutralizing antibody titer test was carried out in accordance with the National Standard of the People's Republic of China "Animal Rabies Virus Neutralizing Antibody Detection Technology GB / T34739-2017". The virus was challenged by intracranial injection of 50LD on day 28. 50 Rabies virus CVS-11 strain, observe and record the survival of mice. Figure 6 As shown, oral single immunization 10 7 FFU or 10 6 FFU, the neutralizing antibody titers of mice were higher than the rabies virus immune replacement level defined by the WHO (RVNA ≥ 0.5 IU), and could completely protect mice from rabies virus attack.

[0073] 2. Immunization of mice with the recombinant virus rVSV-RABV GG ΔM51 via Aedes aegypti delivery The recombinant virus rVSV-RABV GG ΔM51 prepared in Example 1 was inoculated with Aedes aegypti through blood sucking. Mice were immunized by feeding or biting, with 12 mice in each group. In the experimental group immunized by feeding, the Aedes aegypti mosquitoes infected 12 days after infection were divided into 20 tubes and ground, and each mouse was fed a tube of grinding liquid. In the experimental group immunized by biting, the Aedes aegypti mosquitoes infected 12 days after infection were divided into 12 cages, with 20 in each cage, and each cage bit a BALB / c mouse, biting once every 28 days, for a total of 2 bites. Blood was collected 28 days after inoculation to detect the neutralizing antibody titer. The neutralizing antibody titer detection was carried out in accordance with the National Standard of the People's Republic of China "Animal Rabies Virus Neutralizing Antibody Detection Technology GB / T34739-2017". And on the 28th day, 50LD of poison was injected intracranially. 50 Rabies virus CVS-11 strain, observe and record the survival of mice. Figure 7 As shown, the neutralizing antibody titers of mice immunized by feeding were higher than the rabies virus immune replacement level defined by WHO (RVNA ≥ 0.5 IU), and could completely protect mice from rabies virus attack. The protection rate of mice immunized by biting could reach 60% after attack.

[0074] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.

Claims

1. A recombinant virus, characterized in that The recombinant virus is a recombinant vesicular stomatitis virus expressing rabies virus G protein.

2. The recombinant virus according to claim 1, characterized in that The amino acid sequence of the rabies virus G protein is shown in SEQ ID No.

2.

3. The recombinant virus according to claim 1 or 2, characterized in that The recombinant virus contains a nucleic acid molecule encoding the rabies virus G protein according to claim 1 or 2, and the nucleic acid molecule is located between the M protein gene and the G protein gene of the vesicular stomatitis virus.

4. A method for preparing the recombinant virus according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: A1) introducing the nucleic acid molecule encoding the rabies virus G protein according to claim 1 or 2 into a vesicular stomatitis virus vector to obtain a recombinant vesicular stomatitis virus vector expressing the rabies virus G protein; A2) rescuing the recombinant vesicular stomatitis virus vector to obtain the recombinant virus.

5. The method according to claim 4, characterized in that The introduction in A1) is to introduce the nucleic acid molecule between the M protein gene and the G protein gene of the vesicular stomatitis virus vector.

6. The method according to claim 4 or 5, characterized in that: The vesicular stomatitis virus vector is rVSV-G ΔM51.

7. The recombinant vesicular stomatitis virus vector according to any one of claims 4 to 6.

8. A vaccine prepared from the recombinant virus described in any one of claims 1 to 3 or the recombinant vesicular stomatitis virus vector described in claim 7.

9. Use of the recombinant virus according to any one of claims 1 to 3 or the recombinant vesicular stomatitis virus vector according to claim 7 in the preparation of a product for preventing rabies virus infection or rabies.

10. A method for preparing insects for immunization, characterized in that: The method comprises infecting insects with the recombinant virus described in any one of claims 1 to 3 to obtain the insects for immunization.

Citation Information

Cited By

  • Recombinant vesicular stomatitis virus carrying schmallenberg virus gene as well as preparation and application of recombinant vesicular stomatitis virus

    CN119592524A

  • Rabies virus glycoprotein chimeric recombinant vesicular stomatitis virus and application thereof

    CN120442567A

  • Non-neurotoxic recombinant live virus vector rabies vaccine

    WO2026183992A1